Onkologie. 2022:16(3):151-154 | DOI: 10.36290/xon.2022.029

Severe secondary immune thrombocytopenia in a patient with chronic lymphocytic leukemia

Dominika Écsiová1, Pavel Vodárek1, Petra Rozsívalová2, 3, Filip Vrbacký1, Kateřina Hrochová4, Petr Hoffmann5, Pavel Žák1, Lukáš Smolej1, Martin Šimkovič1
1 IV. interní hematologická klinika, Fakultní nemocnice v Hradci Králové, Lékařská fakulta Univerzity Karlovy v Hradci Králové
2 Oddělení klinické farmacie, Fakultní nemocnice v Hradci Králové
3 Katedra sociální a klinické farmacie, Farmaceutická fakulta Univerzity Karlovy v Hradci Králové
4 Ústav klinické biochemie a diagnostiky, Fakultní nemocnice v Hradci Králové
5 Radiologická klinika, Fakultní nemocnice v Hradci Králové

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Euro-American population and is often complicated by autoimmune cytopenias. In patients with anemia and thrombocytopenia, one of the possible causes is autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and rarely pure red cell aplasia (PRCA). For the last few years, oral targeted inhibitors have been available for the treatment of CLL. The use of these molecules has significantly improved the prognosis of patients. Our case report describes the successful administration of thrombopoietin receptor agonist eltrombopag before targeted therapy with the Bruton tyrosine kinase inhibitor ibrutinib in a patient with secondary ITP.

Keywords: chronic lymphocytic leukemia, immune thrombocytopenia, ibrutinib, eltrombopag, thrombopoietin receptor agonists.

Published: May 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Écsiová D, Vodárek P, Rozsívalová P, Vrbacký F, Hrochová K, Hoffmann P, et al.. Severe secondary immune thrombocytopenia in a patient with chronic lymphocytic leukemia. Onkologie. 2022;16(3):151-154. doi: 10.36290/xon.2022.029.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679-1705. Go to original source... Go to PubMed...
    2. Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010;116(23):4771-4776. Go to original source... Go to PubMed...
    3. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. doi:10.1182/blood-2017-09-806398. Go to original source... Go to PubMed...
    4. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995;43(2):130-137. Go to original source... Go to PubMed...
    5. Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 2008;56(10):1926-1931. Go to original source... Go to PubMed...
    6. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874-879. Go to original source... Go to PubMed...
    7. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237-2247. Go to original source... Go to PubMed...
    8. Paul S, Jain N, Ferrajoli A, et al. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol. 2019;185(3):606-608. Go to original source... Go to PubMed...
    9. Jolliffe E, Romeril K. Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia. Intern Med J. 2014;44(7):697-699. Go to original source... Go to PubMed...
    10. Luis Miguel JS, Juan José GF. Successful Long-Term Use of Eltrombopag in a Patient with Refractory Severe Thrombocytopenia Associated with Chronic Lymphocytic Leukemia That Allowed Oral Anticoagulant Treatment for Severe Cardiomyopathy. Case Rep Hematol. 2017;2017:9538920. Go to original source... Go to PubMed...
    11. Chang H, Shih LY. Chronic lymphocytic leukemia-associated refractory immune thrombocytopenia successfully treated with eltrombopag. Tumori. 2015;101(2):e49-50. Go to original source... Go to PubMed...
    12. Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783-787. Go to original source... Go to PubMed...
    13. Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991-3995. Go to original source... Go to PubMed...
    14. De Back TR, Kater AP, Tonino SH. Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations. Expert Rev Hematol. 2018;11(8):613-624. Go to original source... Go to PubMed...
    15. Fattizzo B, Barcellini W. Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects. Front Oncol. 2019;9:1435. Go to original source... Go to PubMed...
    16. Visco C, Ruggeri M, Laura Evangelista M, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008;111(3):1110-1116. Go to original source... Go to PubMed...
    17. Kaufman M, Limaye SA, Driscoll N, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(6):892-899. Go to original source... Go to PubMed...
    18. Smolej L, Špaček M, Pospíšilová Š, et al. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie. TaH, 2021; No.1: p. 91-106.
    19. Allan JN, Shanafelt T, Wiestner A, et al. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. Br J Haematol. 2022;196(4):947-953. doi:10.1111/bjh.17984. Go to original source... Go to PubMed...
    20. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43-56. Go to original source... Go to PubMed...
    21. Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188-1200. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.